التفاصيل البيبلوغرافية
| العنوان: |
Prevalence of contraindicated combinations amid behavioral and mental health medications filled in a pediatric population. |
| المؤلفون: |
Borgelt, Laura M., Bliss, Kathryn, Matson, Jacqueline, Cajuste, Bosede, Kuang, Xiaoying, Toohey, Monica, Pace, Wilson, Shemesh, Eyal, Lo, Suzanne, Olczyk, Anna, Gleason, Kristine, Pincus, Harold, Kleinman, Lawrence C. |
| المصدر: |
BMC Primary Care; 7/30/2024, Vol. 25 Issue 1, p1-10, 10p |
| مصطلحات موضوعية: |
MENTAL illness drug therapy, COMBINATION drug therapy, CROSS-sectional method, RESEARCH funding, ZIPRASIDONE, OUTPATIENT medical care, SCIENTIFIC observation, DESCRIPTIVE statistics, DISEASE prevalence, POLYPHARMACY, PEDIATRICS, DRUG interactions, MEDICAID, DRUGS, CHILDREN |
| مصطلحات جغرافية: |
NEW York (State) |
| مستخلص: |
Background: Behavioral or mental health disorders are common in children, adolescents, and young adults. Medication use is increasingly common, with few data describing drug-drug combinations in ambulatory settings. The objectives of this study were to describe the pharmaco-epidemiology of behavioral and mental health (BMH) medications among children, adolescents, and young adults in New York Medicaid and assess the prevalence of contraindicated drug pairs within this population. Methods: This observational cross-sectional study evaluated New York State Medicaid managed care and fee-for-service enrollees under 21 years of age dispensed BMH medications in 2014. Main outcomes included number of members with prescriptions filled; number filling > 1 medication prescription concurrently for ≥ 30 days (polypharmacy), and number and nature of potentially contraindicated drug pairs. Results: Of 2,430,434 children, adolescents, and young adults, 422,486 (17.4%) had a visit associated with a BMH diagnosis and 141,363 (5.8%) received one or more BMH medications. With 84 distinct medications evaluated, polypharmacy was common, experienced by 53,388 individuals (37.8% of those with a prescription filled), generating 11,115 distinct drug combinations. 392 individuals filled prescriptions for a contraindicated pair of ≥ 2 BMH medications for 30 days or longer. With ≥ 1 day overlap, 651 were exposed to contraindicated medications. The most common contraindicated pairs increased potential risk for prolonged QT interval and serotonin syndrome (n = 378 and n = 250 patients, respectively). Most combinations involved ziprasidone (3247.1 per 10,000 ziprasidone prescriptions filled). Conclusions: With nearly 6% of members dispensed a BMH medication, contraindicated drug pairs were uncommon. However, any of those combinations represent a potential risk. Clinicians should attend to the balance of potential risks and benefits before contraindicated pairs are dispensed. The methodology described could serve as a basis for monitoring such rare instances and might reduce harm. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Primary Care is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder